Literature DB >> 32146060

Design, synthesis and evaluation of phthalide alkyl tertiary amine derivatives as promising acetylcholinesterase inhibitors with high potency and selectivity against Alzheimer's disease.

Li Luo1, Qing Song2, Yan Li2, Zhongcheng Cao2, Xiaoming Qiang2, Zhenghuai Tan3, Yong Deng4.   

Abstract

A series of phthalide alkyl tertiary amine derivatives were designed, synthesized and evaluated as potential multi-target agents against Alzheimer's disease (AD). The results indicated that almost all the compounds displayed significant AChE inhibitory and selective activities. Besides, most of the derivatives exhibited increased self-induced Aβ1-42 aggregation inhibitory activity compared to the lead compound dl-NBP, and some compounds also exerted good antioxidant activity. Specifically, compound I-8 showed the highest inhibitory potency toward AChE (IC50 = 2.66 nM), which was significantly better than Donepezil (IC50 = 26.4 nM). Moreover, molecular docking studies revealed that compound I-8 could bind to both the catalytic active site and peripheral anionic site of AChE. Furthermore, compound I-8 displayed excellent BBB permeability in vitro. Importantly, the step-down passive avoidance test indicated that I-8 significantly reversed scopolamine-induced memory deficit in mice. Collectively, these results suggested that I-8 might be a potent and selective AChE inhibitor for further anti-AD drug development.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acetylcholinesterase inhibitors; Alzheimer’s disease; Anti-Aβ aggregation; Antioxidant; DL-3-n-butylphthalide derivatives; Multi-target agents

Mesh:

Substances:

Year:  2020        PMID: 32146060     DOI: 10.1016/j.bmc.2020.115400

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  3 in total

1.  Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer's disease.

Authors:  Suresh K Bowroju; Narsimha R Penthala; Naga Rajiv Lakkaniga; Meenakshisundaram Balasubramaniam; Srinivas Ayyadevara; Robert J Shmookler Reis; Peter A Crooks
Journal:  Bioorg Med Chem       Date:  2021-07-14       Impact factor: 3.461

2.  Development of novel N-(6-methanesulfonyl-benzothiazol-2-yl)-3-(4-substituted-piperazin-1-yl)-propionamides with cholinesterase inhibition, anti-β-amyloid aggregation, neuroprotection and cognition enhancing properties for the therapy of Alzheimer's disease.

Authors:  Chandra Bhushan Mishra; Shruti Shalini; Siddharth Gusain; Amresh Prakash; Jyoti Kumari; Shikha Kumari; Anita Kumari Yadav; Andrew M Lynn; Manisha Tiwari
Journal:  RSC Adv       Date:  2020-05-05       Impact factor: 3.361

3.  New Tetrahydroacridine Hybrids with Dichlorobenzoic Acid Moiety Demonstrating Multifunctional Potential for the Treatment of Alzheimer's Disease.

Authors:  Kamila Czarnecka; Małgorzata Girek; Przemysław Wójtowicz; Paweł Kręcisz; Robert Skibiński; Jakub Jończyk; Kamil Łątka; Marek Bajda; Anna Walczak; Grzegorz Galita; Jacek Kabziński; Ireneusz Majsterek; Piotr Szymczyk; Paweł Szymański
Journal:  Int J Mol Sci       Date:  2020-05-26       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.